This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hamden, K. E. Articles by Akula, S. M. Search for Related Content PubMed PubMed Citation Articles by Hamden, K. E. Articles by Akula, S. M.

 Previous Article  |  Next Article 

Journal of Virology, December 2004, p. 13381-13390, Vol. 78, No. 23
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.23.13381-13390.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Raf-Induced Vascular Endothelial Growth Factor Augments Kaposi's Sarcoma-Associated Herpesvirus Infection

Department of Microbiology & Immunology,¹ Department of Pathology, Brody School of Medicine, East Carolina University, Greenville, North Carolina,² Department of Pathology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania³

Received 25 May 2004/ Accepted 27 July 2004

Recombinant green fluorescent protein encoding Kaposi's sarcoma-associated herpesvirus (rKSHV.152) infection of ß-estradiol stimulated human foreskin fibroblasts (HFF) or HFF/B-Raf_[FF]:ER (expressing a weaker form of B-Raf) could be enhanced to levels comparable to that of HFF/B-Raf_[DD]:ER cells by pretreating cells with soluble vascular endothelial growth factor (VEGF). Conversely, VEGF expression and infection efficiency typically observed in ß-estradiol stimulated HFF/B-Raf_[DD]:ER cells could be lowered significantly by treating with VEGF small interfering RNA. In addition, we observed enhancement of the KSHV infection in HFF cells transfected with human VEGF₁₂₁. These results confirm the ability of Raf-induced VEGF to augment KSHV infection of cells.

This article has been cited by other articles:

• Skobeleva, N., Menon, S., Weber, L., Golemis, E. A., Khazak, V. (2007). In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors. Molecular Cancer Therapeutics 6: 898-906 [Abstract] [Full Text]  
• Pan, H., Xie, J., Ye, F., Gao, S.-J. (2006). Modulation of Kaposi's Sarcoma-Associated Herpesvirus Infection and Replication by MEK/ERK, JNK, and p38 Multiple Mitogen-Activated Protein Kinase Pathways during Primary Infection.. J. Virol. 80: 5371-5382 [Abstract] [Full Text]  
• Ford, P. W., Bryan, B. A., Dyson, O. F., Weidner, D. A., Chintalgattu, V., Akula, S. M. (2006). Raf/MEK/ERK signalling triggers reactivation of Kaposi's sarcoma-associated herpesvirus latency.. J. Gen. Virol. 87: 1139-1144 [Abstract] [Full Text]  
• Bryan, B. A., Dyson, O. F., Akula, S. M. (2006). Identifying cellular genes crucial for the reactivation of Kaposi's sarcoma-associated herpesvirus latency.. J. Gen. Virol. 87: 519-529 [Abstract] [Full Text]  
• Akula, S. M., Ford, P. W., Whitman, A. G., Hamden, K. E., Bryan, B. A., Cook, P. P., McCubrey, J. A. (2005). B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells. Blood 105: 4516-4522 [Abstract] [Full Text]